Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease (Q59120722)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Crohn's disease

1 reference

based on heuristic

inferred from title

0 references

Richard N. Fedorak

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Stephan R. Targan

4

object named as

S R Targan

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

author name string

W J Sandborn

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

W J Tremaine

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

D C Wolf

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

C A Sninsky

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

L R Sutherland

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

S B Hanauer

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

J W McDonald

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

B G Feagan

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

K L Isaacs

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

M G Pike

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

D C Mays

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

J J Lipsky

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

S Gordon

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

C S Kleoudis

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

R H Murdock

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

language of work or name

0 references

publication date

1 September 1999

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Gastroenterology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

117

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

527-535

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464128%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

Controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

A controlled trial of azathioprine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

A controlled double blind study of azathioprine in the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Azathioprine metabolism in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Controlled trial of azathioprine in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2899%2970445-2

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q59120722&oldid=1899980197"